Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants With Liver Cirrhosis Who Have Hepatic Decompensation (EMERALD)

NCT06823713 is registered in ClinicalTrials.gov with Resolution Therapeutics Limited as lead sponsor.

NCT NCT06823713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06823713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants With Liver Cirrhosis Who Have Hepatic Decompensation (EMERALD)
Lead sponsor
Resolution Therapeutics Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 15, 2024
Completion date
November 29, 2028
Enrollment
30 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, decompensated, cirrhosis, liver, decompensated cirrhosis, decompensated liver cirrhosis, end-stage liver disease (esld), fibrosis and cirrhosis of liver, liver diseases, steatotic liver disease